Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Multicenter, Pharmacokinetic, and Safety Study in Children (Term Newborn Infants to 23 Months of Age) Undergoing a Contrast-enhanced MRI With an Intravenous Injection of 0.1 mmol/kg BW Gadobutrol 1.0 M

Trial Profile

Open-label, Multicenter, Pharmacokinetic, and Safety Study in Children (Term Newborn Infants to 23 Months of Age) Undergoing a Contrast-enhanced MRI With an Intravenous Injection of 0.1 mmol/kg BW Gadobutrol 1.0 M

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gadobutrol (Primary)
  • Indications Vascular disorders
  • Focus Pharmacokinetics
  • Sponsors Bayer; Bayer HealthCare

Most Recent Events

  • 14 Jul 2015 According to a Bayer HealthCare media release, gadobutrol (Gadovist) has received approval for diagnostic use in pediatric patients less than 2 years of age in the European Union. The approval was based on results from this trial.
  • 22 Jan 2015 New trial record
  • 05 Jan 2015 According to the media release, the US FDA has approved gadobutrol for use with magnetic resonance imaging in pediatric patients less than 2 years of age, including term neonates. Based on the data from this trial, priority review was granted by the FDA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top